ACP-104 in Acutely Psychotic Subjects With Schizophrenia
Launched by ACADIA PHARMACEUTICALS INC. · Jun 21, 2007
Trial Information
Current as of May 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female; 18-60 years of age
- • The subject is physically healthy and medically stable.
- • The subject is able to provide informed consent
- • The subject has been diagnosed with schizophrenia for at least 1 year
- • Currently experiencing an acute episode of psychosis
- • The subject is willing to comply with all study-related events including in-patient hospitalization for at least 3 weeks.
- • The subject has a caregiver who is willing and able to support the subject to ensure compliance with treatment and outpatient visits.
- • If the subject is female, subject must be of non-childbearing potential - OR- if she is capable of becoming pregnant, agrees to commit to use one of the approved methods of contraception, as defined by the protocol.
- Exclusion Criteria:
- • If the subject is a pregnant or lactating (breast-feeding) female.
- • The subject has a significant risk of suicide, homicide, and/or harm to self or others.
- • Subject's psychotic symptoms have not improved with a therapeutic dose of antipsychotic treatment over the last 2 years.
- • The subject is experiencing his/her first episode of schizophrenia.
- • The subject has another psychotic disorder or has a history of autistic disorder or other pervasive developmental disorder (for example, mental retardation).
- • The subject has been prescribed or exposed to clozapine before.
- • The subject has donated blood or plasma within 56 days prior to the Screening Visit.
- • The subject has participated in any clinical study within 30 days prior to the Screening Visit.
- • In addition to the criteria described above, subjects will be evaluated at screening to ensure that all criteria for study participation are met. These evaluations will include specific measures of the subject's health, including psychosis (mental health -the extent to which subject is unable to think clearly), heart condition, and pregnancy status. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline condition does not meet all protocol-specified entry criteria).
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for central nervous system (CNS) disorders. With a strong focus on advancing treatments for conditions such as Parkinson's disease psychosis, schizophrenia, and other neurodegenerative diseases, Acadia leverages cutting-edge science and clinical expertise to address unmet medical needs. The company's commitment to rigorous research and patient-centric approaches aims to improve the quality of life for individuals affected by complex neurological conditions, positioning Acadia as a leader in the CNS therapeutic area.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Saint Louis, Missouri, United States
Austin, Texas, United States
Philadelphia, Pennsylvania, United States
San Diego, California, United States
Anaheim, California, United States
Huntington Beach, California, United States
Atlanta, Georgia, United States
Baltimore, Maryland, United States
Oceanside, California, United States
San Diego, California, United States
Glendale, California, United States
Baltimore, Maryland, United States
Riverside, California, United States
Bradenton, Florida, United States
Kissimmee, Florida, United States
Costa Mesa, California, United States
Kissimmee, Florida, United States
Pico Rivera, California, United States
Paramount, California, United States
Pico Rivera, California, United States
Willingboro, New Jersey, United States
Culver City, California, United States
Garden Grove, California, United States
Anaheim, California, United States
Pasadena, California, United States
Philadelphia, Pennsylvania, United States
Covina, California, United States
Saint Louis, Missouri, United States
Austin, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials